Inclusion is bigger than policy or workplace acronyms. It’s a way of living and fostering greater outcomes, writes Novo Nordisks Jill Fallows Macaluso.

Pharma and biotech companies can use AI to effectively and efficiently communicate with providers and patients, writes Jenna ...

AI is becoming increasingly sophisticated, taking on responsibilities that were once exclusive to human beings. However, there are also disadvantages posed by ethical ...

It was the summer of 2007 when Chris Anzalone, Ph.D., got a call from Arrowhead Research Company. At the time, Anzalone was working as CEO of the Bennet Group, a private equity firm in Washington, D.C ...

The False Claims Act (FCA) and the Anti-Kickback Statute (AKS) are two of the Department of Justice’s (DOJ) primary tools when it comes to fighting fraud. Originally enacted during the Civil War to ...

Kelsey Mullady Unfortunately, too often organizations treat the compliance department as an afterthought and scramble to get practices into place just in time. Worse yet, many organizations silo the ...

In this series, we will monitor emerging policies and priorities from the new Trump administration and its agencies that are expected to have particular effects on healthcare and life science-related ...

The pharmaceutical industry sits on a treasure trove of data, brimming with the potential to revolutionize drug development, enhance patient care, and optimize commercial strategies. Yet, this vast ...

Conferences and trade shows are great places to learn about your competitive environment, as most companies in the industry usually attend these events; this includes competitors, suppliers, customers ...

When working groups at AbbVie first began evaluating the use of digital technologies in clinical trials, the discussions were mostly conceptual. Individuals agonized over the right approach, the ...

As pharmaceutical manufacturers grow, they often pursue external sources of innovation to supplement their own R&D efforts. A recent study found that 45% of drugs in the pipelines of 20 large ...

A substantial share of biopharmaceutical drug launches (>50%) fail to meet their projected analyst forecasts (see also Simon-Kucher Biotech industry study 2019). With considerable investment going ...